Theophil Thomas Sutton, MD | |
10000 Bay Pines Blvd, Bay Pines, FL 33733 | |
(727) 398-6661 | |
Not Available |
Full Name | Theophil Thomas Sutton |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 10000 Bay Pines Blvd, Bay Pines, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356358899 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 41270 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Theophil Thomas Sutton, MD 3717-46th Ave South, Unit 14, St Petersburg, FL 33711-4452 Ph: () - | Theophil Thomas Sutton, MD 10000 Bay Pines Blvd, Bay Pines, FL 33733 Ph: (727) 398-6661 |
News Archive
Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.
Inovio Pharmaceuticals, Inc. announced today that its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.
The Peoria Journal Star highlights a problem the health care industry has been slow to confront: Exchanging health information. "In the computer age, the ability to share health information would appear to be the least of the reform challenges facing the nation's medical industry. 'But different hospitals don't speak to each other.
Researchers who have uncovered the 'monstrous' hidden nature of a molecule involved in prostate cancer say the findings could herald a new form of personalised medicine for patients, with doctors able to use the same molecular target for diagnosis and treatment.
Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (an infoGROUP company) (NASDAQ: IUSA) will present findings of the company's recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week. The hearing will address the issue of fulfilling requirements for fair balance and risk disclosure in internet and social media promotions. The ORC Guideline study examined consumer habits in researching information about pharmaceutical products online.
› Verified 9 days ago